Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA ...

Lawyers inside and outside the US Securities and Exchange Commission (SEC) have speculated that the agency’s new leadership will take a ...

Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic ...

We recently published a list of 12 Best Nasdaq Stocks Under $20 to Buy Now. In this article, we are going to take a look at ...

Investors looking for promising yet lower-priced stocks, particularly those trading under $20 ... significantly above the consensus 1-year median price target of $14. ACADIA Pharmaceuticals Inc.

A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...

Insiders have been trading these 5 stocks: (($ACAD)), (($EPR)), (($APLE)), (($KTOS)) and (($TSE:EFR)). Here is a breakdown of ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a negative FDA news impact. He faces sentencing in May 2025.